P030 Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes (MDS)

Cervera, José; Solé, Françesc; Haase, D.; Luño, Elisa; Such, Esperanza; Nomdedeu, Benet; Costa, DC; Bernal, Teresa; Vallespı́, Teresa; Bueno, José Luis; Pedro, Carme; Mallo, Mar; Ardanaz, María Teresa; Calasanz, María José; Cañizo, Consuelo del; Hernández-Rivas, Jesús M.; Schanz, Julie; Hildebrandt, Barbara; Carbonell, Félix; Orero, Maite; Ramos, Fernando; Marco, Víctor; Tormo, Mar; Gómez, Valle; Andreu, Rafael; Xicoy, Blanca; Amigo, María‐Luz; Munoz, J.; Bonanad, Santiago; Arrizabalaga, Beatriz; Senent, Maria L.; Germing, Ulrich; Sanz, G.F.

doi:10.1016/s0145-2126(09)70110-9

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, UC is not specific to AML. There are reports of dismal prognosis of ALL cases with UC as well as of myelodysplastic syndromes with UC , with the latter suggesting that UC is a property of dysfunctional stem cells. Needless to say, in order to characterise the genetic features of samples with UC, conventional chromosome banding analyses are clearly insufficient.…”

Section: Resultsmentioning

confidence: 99%

Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population‐based series of acute myeloid leukaemia

Lazarević

Hörstedt

Johansson

et al. 2014

European J of Haematology

View full text Add to dashboard Cite

Unsuccessful cytogenetics (UC) in patients with acute myeloid leukaemia (AML) treated on different SWOG trials was recently reported to be associated with increased age and dismal outcome. To ascertain whether this holds true also in unselected patients with AML, we retrieved all cytogenetic reports in cases from the population-based Swedish AML Registry. Between 1997 and 2006, 1737 patients below 80 yr of age without myelosarcoma or acute promyelocytic leukaemia received intensive treatment. The frequencies of UC and unperformed cytogenetics (UPC) were 2.1% and 20%, respectively. The early death rates differed between the cytogenetic subgroups (P = 0.006) with the highest rates in patients with UC (14%) and UPC (12%) followed by high-risk (HR) AML, intermediate risk (IR) and standard risk (SR) cases successfully karyotyped (8.6%, 5.9%, and 5.8%, respectively). The complete remission rate was lower in UC and UPC and HR compared with the other risk groups (P < 0.001). The overall five-year survival rates were 25% for UC and 22% for UPC, whereas the corresponding frequencies for SR, IR and HR AML patients without UC and UPC were 64%, 31% and 15%, respectively. In conclusion, lack of cytogenetic data translates into a poor prognosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population‐based series of acute myeloid leukaemia

Lazarević

Hörstedt

Johansson

et al. 2014

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…However, in certain patients cytogenetic testing does not yield informative results, hindering the application of prognostic schemes, such as IPSS or IPSS‐R and leading to loss of important diagnostic and prognostic information. It is difficult to establish the actual incidence of MC study failure because it is highly variable among centers, but it has been estimated to be about 6–20% (Cervera et al, ; Jiang, ). MDS Spanish Registry and the German‐Austrian MDS Study Group evaluated the characteristics, outcome and prognostic factors of a large series of 247 MDS patients with unsuccessful conventional cytogenetic study, and compared with those of a group of 2,418 patients with successful cytogenetic study (Cervera et al, ).…”

Section: Discussionmentioning

confidence: 99%

“…It is difficult to establish the actual incidence of MC study failure because it is highly variable among centers, but it has been estimated to be about 6–20% (Cervera et al, ; Jiang, ). MDS Spanish Registry and the German‐Austrian MDS Study Group evaluated the characteristics, outcome and prognostic factors of a large series of 247 MDS patients with unsuccessful conventional cytogenetic study, and compared with those of a group of 2,418 patients with successful cytogenetic study (Cervera et al, ). They found that the median OS of patients with unsuccessful cytogenetics was comparable to that of patients belonging to the IPSS intermediate cytogenetic risk category, suggesting that unsuccessful cytogenetics have and independent prognostic impact in MDS.…”

Section: Discussionmentioning

confidence: 99%

“…The International Prognostic Scoring System (IPSS) (Greenberg et al, ), and the recently published revised IPSS (IPSS‐R) (Greenberg et al, ), are the most commonly used prognostic systems for MDS and include variables such as the number and depth of cytopenias, percentage of BM blasts, and karyotype. However, standard MC has technical limitations that result in the underestimation of the degree of chromosomal changes and in some cases may fail to provide results because of the growth of no or few cells in metaphase (Cervera et al, ). Fluorescence in situ hybridization (FISH) may complement the MC study (Cherry et al, ); however, its utility is limited to the detection of particular lesions (Jiang et al, ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing

Arenillas

Mallo

Ramos

et al. 2013

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

Cytogenetic aberrations identified by metaphase cytogenetics (MC) have diagnostic, prognostic, and therapeutic implications in myelodysplastic syndromes (MDS). However, in some MDS patients MC study is unsuccesful. Single nucleotide polymorphism array (SNP-A) based karyotyping could be helpful in these cases. We performed SNP-A in 62 samples from bone marrow or peripheral blood of primary MDS with an unsuccessful MC study. SNP-A analysis enabled the detection of aberrations in 31 (50%) patients. We used the copy number alteration information to apply the International Prognostic Scoring System (IPSS) and we observed differences in survival between the low/intermediate-1 and intermediate-2/high risk patients. We also saw differences in survival between very low/low/intermediate and the high/very high patients when we applied the revised IPSS (IPSS-R). In conclusion, SNP-A can be used successfully in PB samples and the identification of CNA by SNP-A improve the diagnostic and prognostic evaluation of this group of MDS patients.

show abstract

“…Similarly, in myelodysplasia, the presence of UC at diagnosis was associated with worse survival when compared to normal karyotype. (Cervera J et al, 2009)…”

Section: Discussionmentioning

confidence: 99%

Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia

et al. 2013

View full text Add to dashboard Cite

SUMMARY Chromosome banding analysis is the gold standard method for the identification of recurrent cytogenetic abnormalities in acute myeloid leukaemia (AML). It allows stratification of AML patients into subgroups with distinct responses to therapy and survival. Unfortunately a variety of issues hamper cytogenetic evaluation in ~10% of cases (unsuccessful cytogenetics [UC]) and the outcome of these patients is poorly understood. To better define the significance of unsuccessful cytogenetic in patients with AML, we compared the baseline characteristics and the prognostic impact of the 94 (6%) patients, whose standard metaphase analysis yielded unacceptable results, to the remaining 1403 AML patients with successful cytogenetic analysis treated on successive SWOG protocols. The incidence of UC increased with age, with peak incidence in patients older than 60 years. These patients had a lower response rate to induction chemotherapy (complete remission rate of 43%) and dismal 5-year survival rates (16%), which was especially poor in patients older than 60 years (<5%). The complete remission and survival rates were similar to those seen in patients with unfavorable karyotype. The early death rate was not increased. These results suggest that UC increases with age and predict for poor outcomes, similar to the outcomes of patients with unfavorable karyotype.

show abstract

P030 Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes (MDS)

Cited by 6 publications

References 0 publications

Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population‐based series of acute myeloid leukaemia

Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population‐based series of acute myeloid leukaemia

Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing

Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia

Contact Info

Product

Resources

About